InsiderTrades

Form 4 for ACAD ACADIA PHARMACEUTICALS INC

Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-01 · accession 0001415889-24-012237 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-03 2024-05-02 ACAD Schneyer Mark C. EVP, CFO S - Sale+OE $16.94 -3,503 32.1K -10% -$59.3K
D 2024-05-03 2024-05-01 ACAD Schneyer Mark C. EVP, CFO M - OptEx — +6,814 35.6K +24% —
D 2024-05-03 2024-05-01 ACAD Schneyer Mark C. EVP, CFO M - OptEx $0.00 -6,814 20.4K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-02 S D 3,503 $16.94 32,053 D — — (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
2 Common Common Stock 2024-05-01 M A 6,814 — 35,556 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
3 Derivative Restricted Stock Units 2024-05-01 M D 6,814 $0.00 20,445 D — · — to — 6,814 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The restricted stock units vest in four equal annual installments beginning May 1, 2024.